Showing results (31-40 of 492) with videos related to
Sort By:
Pageof 50
JAMA Oncology|October 27, 2022
Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With CancerAngela K Green, Sara M Tabatabai, Carol Aghajanian, et al.Seminars in Oncology|May 15, 2016
ASCO Plenary Sessions: impact, legacy, futureAndrae Vandross, Vinay Prasad, Sham MailankodyJAMA Otolaryngology-- Head & Neck Surgery|July 29, 2014
Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley LectureTito Fojo, Sham Mailankody, Andrew LoNature Reviews. Clinical Oncology|November 14, 2018
Addendum: Low-value approvals and high prices might incentivize ineffective drug developmentVinay Prasad, Christopher McCabe, Sham MailankodySeminars in Hematology|October 6, 2024
Accelerating accessibility of CAR-T/NK therapies - Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?Sridevi Rajeeve, Abhinav Hoskote, Sham MailankodyAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Many Shades of Disparities in Myeloma CareSiddhartha Ganguly, Sham Mailankody, Sikander AilawadhiBlood Cancer Journal|February 6, 2019
Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patientsDickran Kazandjian, Elizabeth Hill, Malin Hultcrantz, et al.Leukemia & Lymphoma|October 15, 2008
Epidemiology, pathology and treatment of non-follicular indolent lymphomasOla Landgren, Hervé TillyBritish Journal of Haematology|January 3, 2024
Early detection of multiple myeloma: A first step towards a screening programmeChristof Scheid, Ola LandgrenClinical Advances in Hematology & Oncology : H&O|November 16, 2019
Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime timeDickran Kazandjian, Ola LandgrenPageof 50